trending Market Intelligence /marketintelligence/en/news-insights/trending/w82np1h9tpm0ywjds1jv3q2 content esgSubNav
In This List

EyeGate Pharmaceuticals names director

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


EyeGate Pharmaceuticals names director

EyeGate Pharmaceuticals Inc. appointed Steven Boyd to its board.

Boyd is the chief investment officer of Armistice Capital, a New York-based equity hedge fund focused on the healthcare and consumer sectors.

Waltham, Mass.-based EyeGate is a clinical-stage specialty pharmaceutical company developing therapies to treat eye-related diseases and disorders.